Cyclin-Dependent Kinase Inhibitors in Combination Chemotherapy
作者： Manish A. Shah , Gary K. Schwartz
DOI: 10.1385/1-59259-864-1:027
关键词:
摘要: Cyclin-dependent kinase inhibitors (CDKIs) represent a new class of anticancer therapeutics. Perturbations in the cell cycle are commonly described carcinogenesis. This novel therapeutics exploits these perturbations to achieve tumor-specific cytotoxicity. In last several years, our understanding cell-cycle regulation has improved with emerging concepts cell-cycle-mediated drug resistance and modulation improve cytotoxic efficacy. It is becoming increasingly apparent that CDKIs may efficacy by functioning as modulators. this chapter, we review field therapeutics, focus on their combinations.
springer.com
springerlink.com参考文章(202)
Goldie Jh, Coldman Aj, A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer treatment reports. ,vol. 63, pp. 1727- 1734 ,(1979)
Jacob Falck, Niels Mailand, Randi G. Syljuåsen, Jiri Bartek, Jiri Lukas, The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. ,vol. 410, pp. 842- 847 ,(2001) , 10.1038/35071124
Makiko Shimizu, Tadakazu Akiyama, Tetsuya Tsujita, Masami Okabe, Tamio Mizukami, Tetsuo Yoshida, Shiro Akinaga, G1 Phase Accumulation Induced by UCN-01 Is Associated with Dephosphorylation of Rb and CDK2 Proteins as well as Induction of CDK Inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated Human Epidermoid Carcinoma A431 Cells Cancer Research. ,vol. 57, pp. 1495- 1501 ,(1997)
Paul Clute, Jonathon Pines, Temporal and spatial control of cyclin B1 destruction in metaphase. Nature Cell Biology. ,vol. 1, pp. 82- 87 ,(1999) , 10.1038/10049
Keith C. Bible, Scott H. Kaufmann, Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Research. ,vol. 57, pp. 3375- 3380 ,(1997)
D S Hawkins, G W Demers, D A Galloway, Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Research. ,vol. 56, pp. 892- 898 ,(1996)
Bert Vogelstein, Kenneth W. Kinzler, Todd Waldman, p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Research. ,vol. 55, pp. 5187- 5190 ,(1995)
P J Farnham, R T Schimke, Transcriptional regulation of mouse dihydrofolate reductase in the cell cycle. Journal of Biological Chemistry. ,vol. 260, pp. 7675- 7680 ,(1985) , 10.1016/S0021-9258(17)39661-8
S Pilotti, M I Colnaghi, G Spatti, S C Righetti, F Zunino, S Ménard, G Della Torre, M A Pierotti, F Ottone, M Cornarotti, S Oriana, G L Bresciani, C Lavarino, S Böhm, A Comparative Study of p53 Gene Mutations, Protein Accumulation, and Response to Cisplatin-based Chemotherapy in Advanced Ovarian Carcinoma Cancer Research. ,vol. 56, pp. 689- 693 ,(1996)
Caroline Dive, Dyfed L. Evans, Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes Cancer Research. ,vol. 53, pp. 2133- 2139 ,(1993)